IBO
Impact BioMedicalยทAMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IBO
Impact Biomedical Inc.
A pharmaceutical research and biomedical intellectual property company
1400 Broadfield Blvd., Suite 130, Houston, TX 77084
--
Impact BioMedical Inc., a Nevada corporation, was founded on October 16, 2018. The company is a subsidiary of DSS, Inc. Through licensing, co-development, joint ventures and other relationships, the company works with external partners to discover, identify and patent unique science and technology that can be developed into new products in the field of human healthcare and wellness.
Company Financials
EPS
IBO has released its 2025 Q2 earnings. EPS was reported at -1.18, versus the expected 0, missing expectations. The chart below visualizes how IBO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
IBO has released its 2025 Q3 earnings report, with revenue of 18.00K, reflecting a YoY change of NaN%, and net profit of -1.48M, showing a YoY change of -134.78%. The Sankey diagram below clearly presents IBO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
